✦
UWELL CLOUD YOU JIAN YUN

LK101 Personalized Cancer Vaccine

Considering LK101? Turn your questions into a clear next step. Uwell helps you organize medical records and coordinate an enquiry with the receiving clinical team.

Start with an enquiry. Clinical suitability is assessed by the treating team.

Explore the patient journeyDownload documents
  1. Tumor profile
  2. Selected neoantigens
  3. mRNA-loaded dendritic cells
  4. T-cell recognition
Conceptual mechanism · not a prediction of treatment response

Move forward with a prepared care enquiry

  • Organize your recordsBring pathology, imaging and treatment history into the conversation.
  • Clarify the clinical pathwayIdentify the access, sample and assessment questions to confirm with the hospital.
  • Plan the practical next stepsExplore coordination support for appointments, language and travel planning.

Personalized to a tumor profile

Likang describes LK101 as a personalized therapeutic vaccine using the patient’s own dendritic cells loaded with tumor-neoantigen mRNA. It is intended for people with cancer, rather than routine vaccination of healthy people.

The proposed mechanism is to present selected tumor neoantigens to T cells, helping the immune system recognize corresponding tumor targets. A biological mechanism does not establish an individual patient’s treatment outcome.

Assessment comes first

The manual discusses postoperative treatment and systemic treatment for selected adults with solid tumors, alone or alongside standard treatment. Cancer type, prior treatment, general health and sample suitability require assessment by the treating team.

Prepare pathology reports, recent imaging, treatment and medication history, and available tumor-sample information for the clinical team. Obtain current collection and transport instructions from the hospital before arranging any sample shipment.

Hospital and access pathway

The supplied technical manual names West China Lecheng Hospital of Sichuan University (四川大学华西乐城医院), Hainan, as the treatment hospital. The team must confirm current access, eligibility and appointments for each enquiry.

The materials refer to clinical-trial clearance and a Lecheng translational-application pathway. Permission to conduct research and a local access pathway should not be described as general drug marketing approval. Ask the hospital which pathway applies to the proposed care.

From assessment to follow-up

  1. Clinical assessment
  2. Tumor sample review
  3. Sequencing and personalized preparation
  4. White-cell collection and vaccine preparation
  5. Treatment and follow-up

The manual estimates about six weeks for sequencing, antigen prediction and mRNA preparation, followed by about three weeks for vaccine preparation after white-cell collection. These are indicative preparation periods, actual treatment and travel scheduling must be confirmed.

Have medical records ready? Start the conversation.

Tell us what you need help with. We can help prepare your enquiry and the questions for the clinical team before you make travel arrangements.

An enquiry does not commit you to treatment.

Understanding the evidence

LK101 is being studied in clinical research. The supplied slides include early study summaries and individual cases; these do not establish a general response rate or prove superiority to standard care. This introduction does not reproduce the conflicting numerical outcome claims.

Read the CT11 study record

Risks to discuss with the clinical team

The manual lists injection-site reactions and flu-like symptoms, as well as potential serious reactions including systemic allergy and cytokine-release syndrome. Monitoring and management belong to the treating clinical team; discuss risks before deciding on treatment.

Beyond LK101: the research pipeline

Research pipeline described in Likang’s English brochure. These entries are not an offer of available treatment, and their current development status is not independently verified here.

LK201
Personalized, multi-target neoantigen-specific T-cell therapy.
LK301
Shared-antigen TCR-T program for mutation-positive tumors.
LK302
Shared-antigen TCR-T program for antigen-expressing tumors.
LK401
Personalized neoantigen TCR-T program.

Your questions

Is this a preventive vaccination?

No. The materials describe a personalized therapeutic approach for patients with cancer. It is different from vaccines used to prevent cancer-causing infections.

Does every solid tumor qualify?

No. A broad list of cancers in a brochure does not establish eligibility. The clinical team reviews each patient and the applicable protocol.

Should I change my existing treatment?

Discuss any change with your treating oncologist. This page does not recommend stopping, delaying or replacing standard treatment.

Can I book travel before assessment?

First confirm clinical assessment, sample requirements and scheduling with the receiving team. Preparation estimates are not confirmed appointment dates.

Take the next step with Uwell

Get help preparing an LK101 enquiry, or compare our coordination services to choose the support you need.

Compare coordination services

Uwell helps coordinate enquiries and medical-record preparation. Eligibility and treatment decisions remain with the clinical team. Medical fees are quoted and collected directly by the provider; Uwell does not collect medical fees.

Download the source documents

Keep the documents for your conversation with the clinical team. These are attributed manufacturer materials with an editorial cover. Some dates and claims remain unverified; patient-case scans are excluded.

Sources and editorial scope

Prepared from the supplied Likang materials and the study records below. Manufacturer statements are attributed; this page is not an independent clinical assessment. Editorial review: 8 September 2026.

Sariyah Ahmad
Active Triage Officer

Welcome to Uwell Cloud. Connecting from Malaysia, Indonesia, or Thailand? Ask me about visa-free travel and stem cell medical programs in Boao Lecheng.